AKER - エイカ―ズ・バイオサイエンス （Akers Biosciences Inc） エイカ―ズ・バイオサイエンス

Akers Biosciences Inc. shares closed this week 21.8% lower than it did at the end of last week. The stock is currently up 33.2% year-to-date, down 0.4% over the past 12 months, and down 99.2% over the past five years. This week, the Dow Jones Industrial Average rose 0.8%, and the S&P 500 fell 2.0%. Trading Activity Shares traded as high as $3.40 and as low as $2.47 this week.Trading volume this week was 41.9% higher than the 10-day average and 68.3% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -633.2% The company's stock price performance over the past 12 months lags the peer average by -100.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Akers Biosciences Inc. shares closed today 16.6% lower than it did at the end of yesterday. The stock is currently up 142.2% year-to-date, up 54.9% over the past 12 months, and down 98.1% over the past five years. Today, the Dow Jones Industrial Average rose 0.3%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $5.24 and as low as $3.40 this week.Shares closed 5e+1% below its 52-week high and 2e+2% above its 52-week low.Trading volume this week was 165.3% higher than the 10-day average and 593.2% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 468.7% The company's stock price performance over the past 12 months lags the peer average by -37.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Akers Biosciences Inc. shares closed this week 21.0% higher than it did at the end of last week. The stock is currently up 88.4% year-to-date, up 20.5% over the past 12 months, and down 98.4% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.3%. Trading Activity Shares traded as high as $4.77 and as low as $3.11 this week.Shares closed 6e+1% below its 52-week high and 1e+2% above its 52-week low.Trading volume this week was 74.0% higher than the 10-day average and 342.7% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 212.2% The company's stock price performance over the past 12 months lags the peer average by -77.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Akers Biosciences Inc. shares closed this week 25.1% higher than it did at the end of last week. The stock is currently up 65.3% year-to-date, down 7.1% over the past 12 months, and down 98.6% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 3.8%. Trading Activity Shares traded as high as $3.34 and as low as $2.62 this week.Trading volume this week was 23.0% higher than the 10-day average and 9.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date beats the peer average by 101.2% The company's stock price performance over the past 12 months lags the peer average by -106.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Norwegian investor snaps up 75 per cent stake in wind and solar developer providing boost for plans to establish global renewable energy major Mainstream Renewable Power has agreed to sell a 75 per cent stake in its business to Norwegian investor Aker Horizons as part of a major equity deal announced yesterday that values the global wind and solar developer at around €1bn. The agreement, which is subject to regulatory approval, provides a boost to Mainstream Renewable Power's plans to bring 5.5GW of wind and solar assets to financial close by 2023 ahead of a planned initial public offering (IPO) on the stock market, the company said. Founded in 2008, the Dublin-based firm has built up significant interests in large scale solar and onshore and offshore wind projects across Latin America, Asia-Pacific, and Africa, and is involved in more than 1.2GW of major capital projects currently under construction. Previous offshore wind developments from the company have also included the 450MW Neart na Gaoithe project in Scotland and the 1.2GW Hornsea One project off the coast of Yorkshire in the UK.

Norwegian investment giant Aker announced Tuesday it had taken a majority stake in Mainstream Renewable Power, the global wind and solar project developer. The transaction sees Aker’s cleantech investment subsidiary Aker Horizons paying 758 million euros (USD $919 million) for a 75 percent stake in Mainstream, valuing the Dublin, Ireland-based developer at €900 million ($1.1 billion). Aker Horizons has also acquired a 50 percent stake in superconducting cable systems developer SuperNode . The deal, which is expected to close in the second quarter of this year subject to regulatory and other approvals, includes a €100 million ($121 million) earn-out payment due in 2023 if Mainstream meets “certain milestones,” Aker said in a press release . IPOs in the pipeline Mainstream’s shareholders, which include founder and chairman Dr. Eddie O’Connor, will reinvest in the business and retain a 25 percent ownership of the company, said Aker. O’Connor is set to stay on as chairman of the board, which will be expanded with the addition of three Aker executives.

Industrial investment company Aker ASA announced today an agreement by its wholly owned subsidiary, Aker Horizons to acquire 75% interest in renewable energy company Mainstream Renewable Power. The deal assigns an equity value to Mainstream of €900 million. Founded in 2008, Mainstream has developed and brought forward assets totaling 6.4 GW of renewable energy capacity […]

The Irish renewable energy investment firm has agreed to sell a 75 per cent equity stake to the Norwegian energy company

NEW YORK, Dec. 19, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Akers Biosciences, Inc. (NASDAQ: AKER) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties…